[{"indications": "Indications\u00a0CCR5-tropic HIV infection in combination\r\nwith other antiretroviral drugs in patients previously treated with\r\nantiretrovirals", "name": "MARAVIROC", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "5 Infections", "5.3 Antiviral drugs", "5.3.1 HIV infection", "Other antiretrovirals"], "cautions": "Cautions\u00a0cardiovascular disease; chronic hepatitis B or C; interactions: Appendix 1 (maraviroc)", "side-effects": "Side-effects\u00a0nausea, diarrhoea, abdominal pain, flatulence,\r\nanorexia, depression, insomnia, malaise, headache, anaemia, rash; less commonly seizures, renal failure, proteinuria, myositis; rarely hepatitis, angina, pancytopenia, granulocytopenia,\r\nStevens-Johnson syndrome; see also Osteonecrosis", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/200277.htm", "doses": ["adult over 18 years, 300\u00a0mg\r\ntwice daily"], "pregnancy": "Pregnancy\u00a0manufacturer advises use only if potential benefit\r\noutweighs risk\u2014toxicity in animal studies"}]